NASDAQ: TKNOAlpha Teknova Inc Stock
$5.76-0.01 (-0.17%)
Updated Apr 17, 2025
TKNO Price
$5.76
Fair Value Price
N/A
Market Cap
$307.80M
52 Week Low
$1.16
52 Week High
$10.37
P/E
-10.11x
P/B
3.74x
P/S
10.34x
PEG
N/A
Dividend Yield
N/A
Revenue
$37.75M
Earnings
-$26.75M
Gross Margin
19.2%
Operating Margin
-69.27%
Profit Margin
-70.9%
Debt to Equity
0.44
Operating Cash Flow
-$12M
Beta
1.34
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TKNO Overview
Alpha Teknova Incorporated provides reagents to pharmaceutical and biotechnology companies as well as academic and government research institutions in the U.S. and internationally. Reagents facilitate the discovery, development, and production of biopharmaceutical products (drug therapies and vaccines) and molecular diagnostics. It also offers contract development and manufacturing services and in vitro diagnostic franchises. Alpha Teknova was founded in 1996 and is headquartered in Hollister, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TKNO's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
TKNO
Ranked#26 of 54
Ranked#26 of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.36 | A | |
| $24.65 | A | |
| $13.76 | A |
Be the first to know about important TKNO news, forecast changes, insider trades & much more!
TKNO News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TKNO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TKNO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TKNO is poor value based on its book value relative to its share price (3.74x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.99x)
P/B vs Industry Valuation
TKNO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TKNO due diligence checks available for Premium users.
Valuation
TKNO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.11x
Industry
20.48x
Market
27.98x
TKNO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.74x
Industry
1.99x
TKNO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TKNO's financial health
Profit margin
Revenue
$9.3M
Net Income
-$5.7M
Profit Margin
-61.7%
TKNO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TKNO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$118.8M
Liabilities
$36.4M
Debt to equity
0.44
TKNO's short-term assets ($42.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TKNO's short-term assets ($42.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TKNO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TKNO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$936.0k
Investing
-$1.4M
Financing
-$87.0k
TKNO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TKNO vs Pharmaceutical Stocks
Alpha Teknova Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.